Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan

BACKGROUND: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is wildly used to treat type 2 diabetes mellitus (T2DM) with mono- or combination-therapy. We review two previously published open-label studies to extract insights on the long-term efficacy and safety of vildagliptin. METHODS: Tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Odawara, Masato, Sagara, Rieko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932694/
https://www.ncbi.nlm.nih.gov/pubmed/27382546
http://dx.doi.org/10.1186/s40200-016-0240-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932694/
https://www.ncbi.nlm.nih.gov/pubmed/27382546
http://dx.doi.org/10.1186/s40200-016-0240-z

Ejemplares similares